Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance

Androgen receptor (AR) plays a critical role in the development and progression of prostate cancer (PCa). Current clinically used antiandrogens such as flutamide, bicalutamide, and newly approved enzalutamide mainly target the hormone binding pocket (HBP) of AR. However, over time, drug resistance i...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Xiaohong, He, Yang, Zhou, Jinming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4371693/
https://www.ncbi.nlm.nih.gov/pubmed/25852559
http://dx.doi.org/10.3389/fphar.2015.00057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4371693/
https://www.ncbi.nlm.nih.gov/pubmed/25852559
http://dx.doi.org/10.3389/fphar.2015.00057

Ejemplares similares